Prospective, multi-centre, randomized, open-label, two-arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-023 and Avastin when given intravenously in patients with Metastatic colorectal cancer

Trial Profile

Prospective, multi-centre, randomized, open-label, two-arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-023 and Avastin when given intravenously in patients with Metastatic colorectal cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Reliance Life Sciences
  • Most Recent Events

    • 26 Jul 2013 Planned end date changed from 2 May 2016 to 26 Jun 2016 as reported by ClinicalTrials.gov.
    • 02 Jul 2013 Planned End Date changed to 2 May 2016.
    • 02 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top